Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference
June 09 2021 - 5:00PM
Business Wire
Omeros Corporation (Nasdaq: OMER), today announced that Gregory
A. Demopulos, M.D., chairman and chief executive officer, will
present at the BofA 2021 Napa BioPharma Virtual Conference next
week. The fireside chat with Bank of America analyst, Geoff
Meacham, PhD, is scheduled for Tuesday, June 15, 2021 at 4:30 p.m.
EDT.
The presentation will be webcast. The live and archived webcasts
can be accessed at https://investor.omeros.com/upcoming-events. The
archived webcast will be available for 30 days.
About Omeros Corporation Omeros is a commercial-stage
biopharmaceutical company committed to discovering, developing and
commercializing small-molecule and protein therapeutics for
large-market and orphan indications targeting inflammation,
immunologic diseases (e.g., complement-mediated diseases and
cancers) and central nervous system disorders. Its commercial
product OMIDRIA® (phenylephrine and ketorolac intraocular solution)
1%/0.3% continues to gain market share in cataract surgery. Omeros’
lead MASP-2 inhibitor narsoplimab targets the lectin pathway of
complement and is the subject of a biologics license application
under priority review by FDA for the treatment of hematopoietic
stem cell transplant-associated thrombotic microangiopathy.
Narsoplimab is also in multiple late-stage clinical development
programs focused on other complement-mediated disorders, including
IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19.
OMS906, Omeros’ inhibitor of MASP-3, the key activator of the
alternative pathway of complement, is in a Phase 1 clinical trial,
and the company’s PDE7 inhibitor program OMS527, targeting
addiction and movement disorders, has successfully completed a
Phase 1 trial. Omeros’ pipeline holds a diverse group of
preclinical programs including a proprietary-asset-enabled
antibody-generating technology and a proprietary GPCR platform
through which it controls 54 GPCR drug targets and their
corresponding compounds. One of these novel targets, GPR174,
modulates a new cancer immunity axis recently discovered by Omeros,
and the company is advancing GPR174-targeting antibodies and
small-molecule inhibitors. For more information about Omeros and
its programs, visit www.omeros.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210609005362/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations 360.668.3701 jennifer@cwcomm.org
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2023 to Apr 2024